Palo Alto Networks, Inc. (PANW)

Theseus Pharmaceuticals Stock Forecast

Stock Price Forecast

The 39 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $210.1, which forecasts a 21.53% increase in the stock price over the next year. The lowest target is $130 and the highest is $235.

Price Target: $210.10 (+21.53%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$130	$210.1	$212.5	$235
Change	-24.80%	+21.53%	+22.92%	+35.93%

Analyst Ratings

The average analyst rating for Theseus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	11	12	12	12	12	11
Buy	19	19	20	20	20	18
Hold	11	11	13	14	14	13
Sell	1	1	0	0	0	0
Strong Sell	1	1	1	1	1	1
Total	43	44	46	47	47	43

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Rudy Kessinger DA Davidson	DA Davidson	Strong Buy Maintains $225 → $215	Strong Buy	Maintains	$225 → $215	+24.36%	Jul 31, 2025
Eric Heath Keybanc	Keybanc	Buy → Hold Downgrades n/a	Buy → Hold	Downgrades	n/a	n/a	Jul 31, 2025
Catharine Trebnick Rosenblatt	Rosenblatt	Strong Buy Maintains $235	Strong Buy	Maintains	$235	+35.93%	Jul 31, 2025
Joseph Gallo Jefferies	Jefferies	Strong Buy Maintains $225 → $235	Strong Buy	Maintains	$225 → $235	+35.93%	Jul 24, 2025
Nehal Chokshi Northland Capital Markets	Northland Capital Markets	Hold Maintains $210 → $177	Hold	Maintains	$210 → $177	+2.38%	May 21, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

9.37B

Increased by 16.74%

from 8.03B

Revenue Next Year

10.68B

Increased by 13.93%

from 9.37B

EPS This Year

3.34

Decreased by -8.25%

from 3.64

EPS Next Year

3.75

Increased by 12.39%

from 3.34

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Jul 31, 2020	Jul 31, 2021	Jul 31, 2022	Jul 31, 2023	Jul 31, 2024	Jul 31, 2025	Jul 31, 2026	Jul 31, 2027
Revenue	3.41B	4.26B	5.50B	6.89B	8.03B	9.37B	10.68B	12.23B
Revenue Growth	17.55%	24.87%	29.26%	25.29%	16.46%	16.74%	13.93%	14.57%
EPS	-0.46	-0.87	-0.45	0.64	3.64	3.34	3.75	4.35
EPS Growth	-	-	-	-	468.75%	-8.25%	12.39%	15.77%
Forward PE	-	-	-	-	-	51.76	46.06	39.78
No. Analysts	-	-	-	-	-	58	58	39

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	9.7B	11.4B	14.2B
Avg	9.4B	10.7B	12.2B
Low	9.0B	10.1B	11.0B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	20.4%	22.1%	33.3%
Avg	16.7%	13.9%	14.6%
Low	12.0%	7.5%	3.4%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	3.45	4.15	5.11
Avg	3.34	3.75	4.35
Low	3.19	3.14	3.87

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-5.1%	24.2%	36.2%
Avg	-8.2%	12.4%	15.8%
Low	-12.5%	-6.1%	3.1%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.